CureVac competitorsClear all

Stemirna's top competitors include RNACure, RNAimmune, Moderna, Regulus Therapeutics, Sarepta Therapeutics and Alnylam Pharmaceuticals.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Stemirna
Stemirna
Stemirna is an RNA technology-based drug development company.
RNACure
RNACure
RNACure is a company that develops a messenger RNA (mRNA) drug discovery platform made from mRNA synthesis.
RNAimmune
RNAimmune
RNAimmune is a company specializing in the field of messenger RNA (mRNA) technology.
Moderna
Moderna
Moderna Therapeutics develops messenger RNA therapeutics that produces human proteins for antibodies inside patient cells.
Regulus Therapeutics
Regulus Therapeutics
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
Sarepta Therapeutics
Sarepta Therapeutics
Sarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Founding Date
Founding Date
2016
Founding Date
2019
Founding Date
N/A
Founding Date
N/A
Founding Date
2007
Founding Date
1980
Founding Date
2002
Type
Type
Private
Type
Private
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Shanghai, CN HQ
Locations
Shanghai, CN HQ
Locations
Gaithersburg, US HQ
Locations
Cambridge, US HQ
Huddinge, SE
Cambridge, US
Norwood, US
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Boulogne Billancourt, FR
Berlin, DE
Dublin, IE
Milano, IT
Chiyoda City, JP
see more
Locations
Cambridge, US HQ
Paris, FR
Milano, IT
Amsterdam, NL
Stockholm, SE
Zug, CH
Maidenhead, GB
Employees
Employees
N/A
Employees
5
Employees
N/A
Employees
8309% increase
Employees
2462% decrease
Employees
74349% increase
Employees
1,32324% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
91.6 b
Valuation ($)
36.5 m
Valuation ($)
7.5 b
Valuation ($)
20.7 b
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
137 k
Twitter followers
813
Twitter followers
3.8 k
Twitter followers
14.5 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
67
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
16
Number of tweets (last 30 days)
31
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
116.1
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
9.4
Average likes per tweet (last 30 days)
9.5
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
87.5%
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
189452
Alexa Website Rank
N/A
Alexa Website Rank
N/A
Alexa Website Rank
67329
Alexa Website Rank
393437
Alexa Website Rank
181719
Alexa Website Rank
347064
Employee Rating
Employee Rating
N/A
Employee Rating
N/A
Employee Rating
N/A
Employee Rating
4
Employee Rating
2.8
Employee Rating
3.6
Employee Rating
4.2

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$803.4m (FY, 2020)
Revenue (est.)
$10m (FY, 2020)
Revenue (est.)
$540.1m (FY, 2020)
Revenue (est.)
$492.9m (FY, 2020)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$7.9m (FY, 2020)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$78.1m (FY, 2020)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
$795.5m (FY, 2020)
Gross profit
N/A
Gross profit
N/A
Gross profit
$414.8m (FY, 2020)
Net income
Net income
N/A
Net income
N/A
Net income
N/A
Net income
($747.1m) (FY, 2020)
Net income
($15.7m) (FY, 2020)
Net income
($554.1m) (FY, 2020)
Net income
($858.3m) (FY, 2020)

Operating

Patent Applications
Patent Applications
2 (May, 2020)
Patent Applications
N/A
Patent Applications
N/A
Patent Applications
250 (May, 2017)
Patent Applications
N/A
Patent Applications
N/A
Patent Applications
N/A
Patents Issued
Patents Issued
2 (May, 2020)
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
100 (Q3, 2018)
Patents Issued
300 (FY, 2016)
Patents Issued
N/A
Patents Issued
N/A
Platforms
Platforms
3 (May, 2020)
Platforms
2 (May, 2020)
Platforms
N/A
Platforms
N/A
Platforms
N/A
Platforms
N/A
Platforms
N/A

Funding

Latest funding round
Latest funding round
$ 188m (6 months ago)
Latest funding round
N/A
Latest funding round
$ 10m (7 months ago)
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
N/A
Total funding raised
Total funding raised
$ 206.5m
Total funding raised
N/A
Total funding raised
$ 12.4m
Total funding raised
$ 1.8b
Total funding raised
$ 10m
Total funding raised
N/A
Total funding raised
$ 1.5b
For sources of this data, please see the company profile

View company profiles

RNACure
HQ
Shanghai, CN
Employees
5

RNACure is a company that develops a messenger RNA (mRNA) drug discovery platform made from mRNA synthesis.

View company
RNAimmune
HQ
Gaithersburg, US

RNAimmune is a company specializing in the field of messenger RNA (mRNA) technology.

View company
Moderna
HQ
Cambridge, US
Employees
830↑ 9% increase

Moderna Therapeutics develops messenger RNA therapeutics that produces human proteins for antibodies inside patient cells.

View company
Regulus Therapeutics
HQ
San Diego, US
Employees
24

Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.

View company